Academic Journal
An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
| العنوان: | An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan |
|---|---|
| المؤلفون: | Hidehisa Saeki, Kanako Ishii, Avani Joshi, Arielle G. Bensimon, Hongbo Yang, Isao Kawaguchi |
| المصدر: | Journal of Dermatological Treatment, Vol 33, Iss 1, Pp 229-239 (2022) |
| بيانات النشر: | Taylor & Francis Group |
| سنة النشر: | 2022 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | psoriasis, risankizumab, cost-effectiveness, japan, Dermatology, RL1-803 |
| الوصف: | Objective To evaluate the cost-effectiveness of risankizumab versus other biologic treatments (adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, and guselkumab) of moderate-to-severe psoriasis in Japan. Methods A Markov cohort-level model was constructed to estimate quality-adjusted life years (QALYs) and costs for each treatment over a lifetime horizon. The model simulated patients’ transition through one line of active biologic therapy followed by best supportive care and death. Transition probabilities were informed by network meta-analyses of Psoriasis Activity and Severity Index responses and adverse event-related discontinuation in clinical trials, as well as published real-world evidence and national mortality rates. Costs were evaluated from the health system, societal, and patient out-of-pocket perspectives. Results Risankizumab was expected to provide 0.30–0.89 additional QALYs versus comparator biologics. Under the health system perspective, incremental cost-effectiveness ratios (ICERs) of risankizumab ranged from ¥2,545,812/QALY versus ustekinumab to ¥6,077,134/QALY versus adalimumab. Societal ICERs were lower, ranging from ¥921,770/QALY to ¥4,350,879/QALY. From the patient perspective, risankizumab was estimated to be cost-saving versus four comparators and was associated with ICERs of <¥500,000/QALY versus the remaining comparators. Conclusion Risankizumab was associated with higher QALYs and, based on typical willingness-to-pay benchmarks (¥5-6.7 million/QALY), considered cost-effective versus other biologics for the treatment of psoriasis in Japan. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0954-6634 1471-1753 |
| Relation: | http://dx.doi.org/10.1080/09546634.2020.1744505; https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753; https://doaj.org/article/61ce8344bc144883950bf8975f3da95f |
| DOI: | 10.1080/09546634.2020.1744505 |
| الاتاحة: | https://doi.org/10.1080/09546634.2020.1744505 https://doaj.org/article/61ce8344bc144883950bf8975f3da95f |
| رقم الانضمام: | edsbas.A4B6CF46 |
| قاعدة البيانات: | BASE |
| تدمد: | 09546634 14711753 |
|---|---|
| DOI: | 10.1080/09546634.2020.1744505 |